

**Table S1. PCR primers used for detection of *E. faecalis* virulence factors.**

Target	Primer	Primer sequence (5'-3')	Amplicon size (bp)	Ref.
<i>esp</i>	<i>esp</i> -F	AATTGATTCTTTAGCATCTGG	510	[20]
	<i>esp</i> -R	AGATTCATCTTTGATTCTTGG		
<i>gelE</i>	<i>gelE</i> -F	TATGACAATGCTTTTTGGGAT	213	[20]
	<i>gelE</i> -R	AGATGCACCCGAAATAATATA		
<i>asaI</i>	<i>asaI</i> -F	GCACGCTATTACGAACTATGA	375	[20]
	<i>asaI</i> -R	TAAGAAAGAACATCACCACGA		
<i>cylA</i>	<i>cylA</i> -F	ACTCGGGGATTGATAGGC	688	[20]
	<i>cylA</i> -R	GCTGCTAAAGCTGCGCTT		
<i>hyl</i>	<i>hyl</i> -F	GACTGACGTCCAAGTTTCCAA	276	[20]
	<i>hyl</i> -R	ACAGAAGAGCTGCAGGAAATG		
<i>agg</i>	<i>agg</i> -F	CCAGTAATCAGTCCAGAAACAACC	406	[21]
	<i>agg</i> -R	TAGCTTTTTTCATTCTTGTGTTTGT		

**Table S2. PCR primers used for *E. faecalis* MLST gene diversity determination.**

Target	Primer	Primer sequence (5'-3')	Amplicon size (bp)	Ref.
<i>gdh</i>	<i>gdh</i> -F	GGCGCACTAAAAGATATGGT	530	[22]
	<i>gdh</i> -R	CCAAGATTGGGCAACTTCGTCCCA		
<i>gyd</i>	<i>gyd</i> -F	CAAACCTGCTTAG CTCCAATGGC	395	[22]
	<i>gyd</i> -R	CATTTTCGTTGTCATACCAAGC		
<i>pstS</i>	<i>pstS</i> -F	CGGAACAGGACTTTTCGC	583	[22]
	<i>pstS</i> -R	ATTTACATCACGTTCTACTTGC		
<i>gki</i>	<i>gki</i> -F	GATTTTGTGGGAATTGGTATGG	438	[22]
	<i>gki</i> -R	ACCATTAAAGCAAAATGATCGC		
<i>aroE</i>	<i>aroE</i> -F	TGGAAAACCTTTACGGAGACAGC	459	[22]
	<i>aroE</i> -R	GTCCTG TCCATTGTTCAAAAGC		
<i>xpt</i>	<i>xpt</i> -F	AAAATGATGGCCGTGTATTAGG,	456	[22]
	<i>xpt</i> -R	AACGTCACCGTTCCTTCACTTA		
<i>yqiL</i>	<i>yqiL</i> -F	CAGCTTAAGTCAAG TAAGTGCCG	436	[22]
	<i>yqiL</i> -R	GAATATCCCTTCTGCTTGTGCT		

**Table S3. PCR primers used for detecting the expression levels of *esp*, *agg*, and *cylA* *E. faecalis* isolates by qRT-PCR.**

Target	Primer	Primer sequence (5'-3')	Amplicon size (bp)	Source or Ref.
<i>recA</i>	<i>recA</i> -F	CGACTAATGTCTCAAGCACTAC	106	This study
	<i>recA</i> -R	CGAACATCACGCCAACTT		
<i>esp</i>	<i>Resp</i> -F	GCATCAGTATTAGTTGGT	196	This study
	<i>Resp</i> -R	TTCCTTGTAACACATCAC		
<i>agg</i>	<i>Ragg</i> -F	CGTTGATAAAGCAGTTGAT	130	This study
	<i>Ragg</i> -R	TTGTAGTTGGTCTACTTCTT		
<i>cylA</i>	<i>RcylA</i> -F	GGAGGATATGGTGACAAT	163	This study
	<i>RcylA</i> -R	TTACTTCTGGAGTTGCTAA		

**Table S4. Biofilm formation according to ST of 98 *E. faecalis* isolates.**

STs (n)	No. (%) of isolates with biofilm phenotype		
	Weak	Strong	All positive
ST4 (3)	2 (66.7)	0 (0.0)	3 (100.0)
ST6 (2)	1 (50.0)	0 (0.0)	1 (50.0)
ST16 (34)	11 (32.4)	7 (20.6)	22 (64.8)
ST21 (1)	0 (0.0)	0 (0.0)	0 (0.0)
ST30 (3)	0 (0.0)	0 (0.0)	0 (0.0)
ST34 (1)	0 (0.0)	0 (0.0)	0 (0.0)
ST40 (3)	0 (0.0)	2 (66.7)	2 (66.7)
ST47 (2)	0 (0.0)	1 (50.0)	2 (100.0)
ST63 (1)	1 (100.0)	0 (0.0)	1 (100.0)
ST69 (1)	0 (0.0)	1 (100.0)	1 (100.0)
ST139 (1)	0 (0.0)	0 (0.0)	1 (100.0)
ST179 (32)	8 (25.0)	0 (0.0)	10 (31.3)
ST202 (1)	0 (0.0)	0 (0.0)	0 (0.0)
ST207 (1)	1 (100.0)	0 (0.0)	1 (100.0)
ST300 (1)	0 (0.0)	0 (0.0)	0 (0.0)
ST403 (1)	0 (0.0)	0 (0.0)	0 (0.0)
ST409 (2)	0 (0.0)	0 (0.0)	1 (50.0)
ST414 (1)	0 (0.0)	0 (0.0)	0 (0.0)
ST480 (3)	0 (0.0)	2 (66.7)	3 (100.0)
ST506 (1)	0 (0.0)	0 (0.0)	0 (0.0)
ST541 (1)	0 (0.0)	0 (0.0)	1 (100.0)
ST585 (1)	0 (0.0)	1 (100.0)	1 (100.0)
ST7480 (1)	0 (0.0)	1 (100.0)	1 (100.0)
<b>Total (98)</b>	<b>24(24.5)</b>	<b>15 (15.3)</b>	<b>51 (52.0)</b>

STs: sequence type;

**Table S5. Correlation between biofilm-forming capacity and antimicrobial sensitivity.**

Antimicrobials	Sensitive or MIC (mg/L)	No. (%) of isolates with biofilm phenotype			<i>P</i> <sup>a</sup>
		Weak	Strong	All positive	
<b>erythromycin</b>	Non-Sensitive (n=96)	26(27.1)	24(25.0)	50(52.1)	<i>0.407</i>
	Sensitive (n=17)	1(5.9)	6(35.3)	7(41.2)	
<b>ciprofloxacin</b>	Non-Sensitive (n=40)	10(25.0)	14(35.0)	24(60.0)	<i>0.133</i>
	Sensitive (n=73)	16(21.9)	17(23.3)	33(45.2)	
<b>tetracycline</b>	Non-Sensitive (n=102)	25(24.5)	29(28.4)	54(52.9)	<i>0.106</i>
	Sensitive (n=11)	2(18.2)	1(9.1)	3(27.3)	
<b>High-level gentamicin</b>	Non-Sensitive (n=63)	13(20.6)	19(30.2)	32(50.8)	<i>0.933</i>
	Sensitive (n=50)	14(28.0)	11(22.0)	25(50.0)	
<b>linezolid</b>	MIC >2 ( n = 18)	5(27.8)	6(33.3)	11(61.1)	<i>0.323</i>
	MIC ≤ 2 (n= 95)	22(23.2)	24(25.4)	46(48.4)	

**MIC:** minimum inhibitory concentration; **High-level gentamicin:** >500mg/L; **Non-Sensitive:** including the resistant and medium isolates; <sup>a</sup>: biofilm phenotype-All positive: Non-Sensitive group vs Sensitive group;